2024
Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease
van der Flier W, Scheltens P, Feldman H, Hansson O, Sano M, Bardtrum L, Johannsen P, Jeppesen R, Hansen C, Leon T, Cummings J. Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e088793. PMCID: PMC11713752, DOI: 10.1002/alz.088793.Peer-Reviewed Original ResearchMini-Mental State Examination scoreBaseline dataCognitive scoresClinical Dementia Rating-SumAlzheimer's diseaseApolipoprotein E4 carrier statusClinical Dementia Rating-Sum of Boxes scoresInclusion of participantsMild cognitive impairmentScreening failure rateProportion of individualsMild dementiaGeographic regionsType 2 diabetesBox scoresAD medicationsClinical characteristicsInclusion criteriaCarrier statusNorth AmericaExamination scoresClinical trial populationsPatient characteristicsCognitive impairmentSmall vessel pathology
2022
Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer’s Disease
Wang K, Xu C, Theeke LA, Xiao D, Luo X, Xie C, Initiative A. Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer’s Disease. Nursing Research 2022, 72: 66-73. PMID: 36097266, DOI: 10.1097/nnr.0000000000000623.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TestAuditory Verbal Learning TestMini-Mental State Examination scoreVerbal Learning TestVerbal memory declineState Examination scoreAPOE ε4 alleleVerbal memory lossDisease Neuroimaging InitiativeVerbal memoryCognitive measuresLearning TestLinear mixed modelsMemory declineMild cognitive impairmentExamination scoresLongitudinal effectsLinear mixed model analysisBaseline Mini-Mental State Examination scorePolygenic hazard scoreCognitive dysfunctionCognitive impairmentMixed model analysisAlzheimer's Disease Neuroimaging InitiativeAlzheimer's diseaseCerebral Volumetric Correlates of Apathy in Alzheimer’s Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort
Chaudhary S, Zhornitsky S, Chao HH, van Dyck CH, Li CR. Cerebral Volumetric Correlates of Apathy in Alzheimer’s Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort. Journal Of Alzheimer’s Disease 2022, 85: 1251-1265. PMID: 34924392, PMCID: PMC9215906, DOI: 10.3233/jad-215316.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseInferior frontal gyrusIndependent cohortEmotional scoresHealthy controlsCognitive impairmentVolumetric correlatesMini-Mental State Examination scoreAD/mild cognitive impairmentNeuroanatomical correlatesState Examination scoreApathy Evaluation ScaleGray matter volumeVoxel-based morphometryRight inferior frontal gyrusLabel-based reviewMild cognitive impairmentNormal older adultsCortical atrophyHigh morbidityBasal gangliaRight putamenMatter volumeAnterior cingulateReduced quality
2021
Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations
Jacobs H, Becker A, Kwong K, Engels N, Prokopiou P, Papp K, Properzi M, Hampton O, Sanchez J, Rentz D, Fakhri G, Normandin M, Bennett D, Sperling R, Johnson K. Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056391.Peer-Reviewed Original ResearchHarvard Aging Brain StudyMini-Mental State ExaminationLC integrityLocus coeruleusMini-Mental State Examination scoreNeuronal densityTangle densityLocus coeruleus integrityAging Brain StudyTau pathologyAlzheimer's diseaseAD-related processesVertex-wiseTemporal regionsBraak stageLC measurementsMini-MentalMCI/AD patientsState ExaminationBrain studiesPiB-PET imagingTau-PETPET measurementsPiB-PETTangle burdenVisual trajectories and risk of physical and cognitive impairment among older Chinese adults
Cao G, Wang K, Han L, Zhang Q, Yao S, Chen Z, Huang Z, Luo Y, Hu Y, Xu B. Visual trajectories and risk of physical and cognitive impairment among older Chinese adults. Journal Of The American Geriatrics Society 2021, 69: 2877-2887. PMID: 34111310, DOI: 10.1111/jgs.17311.Peer-Reviewed Original ResearchConceptsOlder Chinese adultsIADL disabilityCognitive impairmentChinese adultsADL disabilityFunctional impairmentCognitive functionMini-Mental State Examination scoreProgressive declineChinese Longitudinal Healthy Longevity SurveyState Examination scoreModerate declineGroup-based trajectory modelsKatz scaleLawton scalePotential confoundersLongevity SurveyImpairmentDecline trajectoriesChinese versionDisabilityLongitudinal studyAdultsRiskExamination scores
2019
Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer’s disease
Sheu JJ, Yang LY, Sanotra MR, Wang ST, Lu HT, Kam RSY, Hsu IU, Kao SH, Lee CK, Shieh JC, Lin YF. Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer’s disease. Clinical Biochemistry 2019, 76: 24-30. PMID: 31786207, DOI: 10.1016/j.clinbiochem.2019.11.011.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAD seraAD patientsEarly diagnosisAD model mouse brainsC-terminal APP fragmentsMini-Mental State Examination scoreSerum samplesHealthy control subjectsState Examination scoreBlood-based biomarkersModel mouse brainProbable Alzheimer's diseaseAge-dependent mannerGood diagnostic performanceHC seraControl subjectsAPP fragmentsAD biomarkersMouse brainYounger ageAD diagnosisNeuronal cellsWestern blottingDiseaseEffect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology 2019, 76: 1219-1229. PMID: 31329216, PMCID: PMC6646979, DOI: 10.1001/jamaneurol.2019.2050.Peer-Reviewed Original ResearchAZD0530 treatmentAdverse eventsPrimary outcomeTreatment groupsAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseasePositron emission tomography evidenceMini-Mental State Examination scoreAlzheimer's Disease Assessment Scale-cognitive subscaleCerebral metabolic declineFrequent adverse eventsSecondary end pointsCerebral metabolic rateMild Alzheimer's dementiaState Examination scorePlasma drug levelsClinical Dementia RatingVolumetric magnetic resonanceEffect of AZD0530Neuronal cell surfaceModified intentionTreat populationSecondary outcomesNeuropsychiatric InventoryEfficacy analysisThe Epidemiology of Patient‐Reported Hypersomnia in Persons With Advanced Age
Miner B, Gill TM, Yaggi HK, Redeker NS, Van Ness PH, Han L, Fragoso C. The Epidemiology of Patient‐Reported Hypersomnia in Persons With Advanced Age. Journal Of The American Geriatrics Society 2019, 67: 2545-2552. PMID: 31390046, PMCID: PMC6898735, DOI: 10.1111/jgs.16107.Peer-Reviewed Original ResearchConceptsSelf-reported sleep-disordered breathingRestless legs syndromeMean ESS scoreCommunity-dwelling personsESS scoreCross-sectional associationsAdvanced ageHypersomnia symptomsCentral nervous system depressant medicationsEpworth Sleepiness Scale scoreMini-Mental State Examination scoreEpidemiologic Studies-Depression scoreSelf-reported medical conditionsEpidemiology of patientsLow physical activitySleep-disordered breathingBody mass indexPhysical Activity ScalePrecipitating Events ProjectState Examination scoreInsomnia Severity IndexMultivariable regression modelsDepressant medicationsClinical characteristicsCross-sectional design
2018
Association of the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly African American Adults With Type 2 Diabetes
Beeri M, Lin H, Sano M, Ravona-Springer R, Liu X, Bendlin B, Gleason C, Guerrero-Berroa E, Soleimani L, Launer L, Ehrenberg S, Lache O, Seligman Y, Levy A. Association of the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly African American Adults With Type 2 Diabetes. JAMA Network Open 2018, 1: e184458. PMID: 30646354, PMCID: PMC6324406, DOI: 10.1001/jamanetworkopen.2018.4458.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationMini-Mental State Examination scoreAfrican American adultsIndividuals of white race/ethnicityAfrican American individualsBaseline MMSE scoreType 2 diabetesAmerican adultsWhite race/ethnicityDementia riskHp 1-1 genotypeCognitive functionMMSE scoreAmerican individualsCognitive declineElevated dementia riskRates of type 2 diabetesAssociated with more cognitive impairmentAssociated with poorer cognitive functionHp genotypeAssociated with poorer cognitionFaster cognitive declineAfrican American participantsPoorer cognitive functionAfrican American study participantsElevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141–147 in Taiwanese with Alzheimer's disease
Lin CY, Sheu JJ, Tsai IS, Wang ST, Yang LY, Hsu IU, Chang HW, Lee HM, Kao SH, Lee CK, Chen CH, Lin YF. Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141–147 in Taiwanese with Alzheimer's disease. Clinical Biochemistry 2018, 56: 75-82. PMID: 29680706, DOI: 10.1016/j.clinbiochem.2018.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseAntibody SpecificityApolipoprotein A-IAutoantibodiesAutoimmunityBiomarkersCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunoglobulin MLysineMalePeptide FragmentsProtein Processing, Post-TranslationalPsychiatric Status Rating ScalesROC CurveTaiwanUp-RegulationConceptsAdvanced glycation end productsSpecific advanced glycation end productsAlzheimer's diseaseMini-Mental State Examination scoreMental State Examination scoreEarly AD markersEarly AD pathologyState Examination scoreEarly disease statesGlycation end productsRelated autoantibodiesAD markersIgM levelsAD pathologyElevated IgMAD seraAD patientsDisease progressionAD biomarkersApolipoprotein A1IgMAutoantibodiesApoA1Serum samplesWestern blottingLong-Term Cognitive Decline After Newly Diagnosed Heart Failure
Hammond CA, Blades NJ, Chaudhry SI, Dodson JA, Longstreth WT, Heckbert SR, Psaty BM, Arnold AM, Dublin S, Sitlani CM, Gardin JM, Thielke SM, Nanna MG, Gottesman RF, Newman AB, Thacker EL. Long-Term Cognitive Decline After Newly Diagnosed Heart Failure. Circulation Heart Failure 2018, 11: e004476. PMID: 29523517, PMCID: PMC6072263, DOI: 10.1161/circheartfailure.117.004476.Peer-Reviewed Original ResearchConceptsIncident heart failureHeart failureYears of ageEjection fractionHF diagnosisAtrial fibrillationModified Mini-Mental State Examination scoresCommunity-based prospective cohort studyCognitive declineHistory of HFMini-Mental State Examination scoreLong-term cognitive declineModified Mini-Mental State ExaminationAtrial fibrillation statusComorbid atrial fibrillationMini-Mental State ExaminationProspective cohort studyGlobal cognitive abilityState Examination scoreHospital discharge summariesPublic health implicationsCohort studyClinical strokeCardiovascular healthAdjusted model
2017
Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial
Furie KL, Viscoli CM, Gorman M, Ford GA, Young LH, Inzucchi SE, Guarino PD, Lovejoy AM, Conwit R, Tanne D, Kernan WN. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. Journal Of Neurology Neurosurgery & Psychiatry 2017, 89: 21. PMID: 28939682, DOI: 10.1136/jnnp-2017-316361.Peer-Reviewed Original ResearchConceptsTransient ischemic attackRecent ischemic strokeIschemic strokeCognitive functionHomeostasis model assessment insulin resistance scoreModified Mini-Mental State Examination scoresAssessment-insulin resistance scoreMini-Mental State Examination scoreInsulin Resistance InterventionPoststroke cognitive functionVascular risk factorsEffect of pioglitazoneInsulin-resistant patientsState Examination scoreIschemic attackPioglitazone groupPlacebo groupIRIS trialStroke trialsCerebrovascular diseaseInsulin resistanceRisk factorsCognitive dysfunctionPatientsResistance Intervention
2016
Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer’s Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis
Kim B, Lee S, Graham P, Angelucci F, Lucia A, Pareja-Galeano H, Leyhe T, Turana Y, Lee I, Yoon J, Shin J. Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer’s Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis. Molecular Neurobiology 2016, 54: 7297-7311. PMID: 27815832, DOI: 10.1007/s12035-016-0192-9.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorPeripheral blood BDNF levelsBlood BDNF levelsBrain-derived neurotrophic factor levelsBDNF levelsPeripheral BDNF levelsMeta-analysisMild cognitive impairmentMini-Mental State ExaminationSystematic reviewNeurotrophic factor levelsStatistically significant differenceAD patientsCognitive impairmentComprehensive systematic reviewSubgroup analysisHealthy controlsNeurotrophic factorAlzheimer's diseaseTrophic effectsPatientsBlood biomarkersInclusion criteriaMini-Mental State Examination scoreSignificant difference
2015
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's Research & Therapy 2015, 7: 35. PMID: 25874001, PMCID: PMC4396171, DOI: 10.1186/s13195-015-0119-0.Peer-Reviewed Original ResearchRegional cerebral glucose metabolismCerebral glucose metabolismTreatment of patientsClinical efficacy measuresModerate Alzheimer's diseaseAlzheimer's diseaseEfficacy measuresGlucose metabolismCentral nervous system availabilityMultiple ascending dose studyFluorodeoxyglucose positron emission tomographyPhase IIa clinical trialMini-Mental State Examination scoreCentral nervous system penetrationPromising new therapeutic targetCSF drug levelsMultiple ascending doseOligomeric amyloid betaPhase Ib trialPlacebo-controlled trialAscending dose studyCongestive heart failureCerebrospinal fluid penetrationDisease-modifying therapiesIIa clinical trial
2014
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
Beal M, Oakes D, Shoulson I, Henchcliffe C, Galpern W, Haas R, Juncos J, Nutt J, Voss T, Ravina B, Shults C, Helles K, Snively V, Lew M, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters C, Figueroa A, Arkun A, Brodsky M, Ondo W, Hunter C, Jimenez-Shahed J, Palao A, Miyasaki J, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell D, Cotto C, Friedman J, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford D, Grimes D, Cote D, Conway J, Siderowf A, Evatt M, Sommerfeld B, Lieberman A, Okun M, Rodriguez R, Merritt S, Swartz C, Martin W, King P, Stover N, Guthrie S, Watts R, Ahmed A, Fernandez H, Winters A, Mari Z, Dawson T, Dunlop B, Feigin A, Shannon B, Nirenberg M, Ogg M, Ellias S, Thomas C, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser R, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi K, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson V, Markind S, Pelikan M, Perlmutter J, Hartlein J, Molho E, Evans S, Adler C, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey M, Hermanowicz N, Niswonger S, Shill H, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer K, Bergholte J, Propsom C, Stacy M, Field J, Mihaila D, Chilton M, Uc E, Sieren J, Simon D, Kraics L, Silver A, Boyd J, Hamill R, Ingvoldstad C, Young J, Thomas K, Kostyk S, Wojcieszek J, Pfeiffer R, Panisset M, Beland M, Reich S, Cines M, Zappala N, Rivest J, Zweig R, Lumina L, Hilliard C, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang U, Young J, Rao J, Cook M, Severt L, Boyar K. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurology 2014, 71: 543-552. PMID: 24664227, DOI: 10.1001/jamaneurol.2014.131.Peer-Reviewed Original ResearchConceptsTotal UPDRS scoresUPDRS scoresCoenzyme Q10PD medicationsFinal visitClinical benefitClinical trialsEarly-phase human studiesPrevious phase II studyDouble-blind clinical trialMini-Mental State Examination scoreParticipants 30 yearsPhase III randomizedPrespecified futility criterionDrug-induced parkinsonismPhase II studyActive treatment groupIU/dEarly Parkinson's diseaseHistory of strokePossible clinical benefitPrimary outcome measureState Examination scoreParkinson's disease modelDiagnosis of PD
2011
Antidepressant Use and Cognitive Functioning in Older Medical Patients With Major or Minor Depression
Han L, McCusker J, Cole M, apek R, Abrahamowicz M. Antidepressant Use and Cognitive Functioning in Older Medical Patients With Major or Minor Depression. Journal Of Clinical Psychopharmacology 2011, 31: 429-435. PMID: 21694621, PMCID: PMC3558972, DOI: 10.1097/jcp.0b013e318221b2f8.Peer-Reviewed Original ResearchConceptsOlder medical patientsAntidepressant useMinor depressionMedical patientsAntidepressant medicationMini-Mental State Examination scoreHamilton Depression Rating ScaleMini-Mental State ExaminationProvincial prescription databasePsychotropic drug useDepression Rating ScaleAcute care hospitalsState Examination scoreComplex medical conditionsLong-term cognitive effectsSignificant cognitive impairmentSmall cognitive improvementsAntidepressant prescriptionsCare hospitalConcomitant benzodiazepinesMedical inpatientsPrescription databaseAntidepressant agentsDepression diagnosisMajor depressionThe Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Sabuncu M, Desikan R, Sepulcre J, Yeo B, Liu H, Schmansky N, Reuter M, Weiner M, Buckner R, Sperling R, Fischl B, Initiative F. The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease. JAMA Neurology 2011, 68: 1040-1048. PMID: 21825241, PMCID: PMC3248949, DOI: 10.1001/archneurol.2011.167.Peer-Reviewed Original ResearchConceptsMini-Mental State Examination scoreHippocampal volume lossMini-MentalDecreased cognitive performanceCognitive performanceExamination scoresCortical thinningCortical regionsMeasures of cognitive performanceMulticenter case-control studyBaseline hippocampal volumeRate of hippocampal volume lossStudies of neuroimagingMild cognitive impairmentCross-subject analysisAnnual rate of hippocampal volume lossAlzheimer's Disease Neuroimaging InitiativeStudy participantsDementia stagesVolume lossHippocampal volumeIndicators of ADCognitive impairmentHippocampal atrophyLongitudinal atrophy
2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial
Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal L, Study F. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. JAMA 2000, 283: 1007-1015. PMID: 10697060, DOI: 10.1001/jama.283.8.1007.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyModerate Alzheimer's diseaseSecondary outcome measuresReplacement therapyAlzheimer's diseaseOutcome measuresClinical trialsPlacebo-controlled clinical trialMini-Mental State Examination scoreAlzheimer's Disease Cooperative StudyPrevention of ADClinical Dementia Rating ScaleClinical Global ImpressionPrimary outcome measureTreatment of mildSmall clinical trialsRole of estrogenState Examination scoreDementia Rating ScaleCGIC scoresEstrogen groupPlacebo groupControlled TrialsFunctional outcomeGlobal Impression
1997
Predictors of recovery in activities of daily living among disabled older persons living in the community
Gill T, Robison J, Tinetti M. Predictors of recovery in activities of daily living among disabled older persons living in the community. Journal Of General Internal Medicine 1997, 12: 757-762. PMID: 9436895, PMCID: PMC1497202, DOI: 10.1046/j.1525-1497.1997.07161.x.Peer-Reviewed Original ResearchConceptsGood nutritional statusADL functionDisabled older personsNutritional statusADL recoveryDaily livingFolstein Mini-Mental State Examination (MMSE) scoresOlder personsMini-Mental State Examination scoreMarkers of resiliencyProspective cohort studyPredictors of recoveryState Examination scoreIntact cognitive functionCohort studyMultivariable analysisMore ADLsMMSE scoresSelf-efficacy scoresHome assessmentBivariate analysisCognitive functionGeneral communityPhysical performanceADL
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply